In the healthcare sector, numerous funds offer different types of investment exposure, yet each follows a distinct strategic path. The iShares U.S. Pharmaceutical ETF (IHE) focuses on U.S.-based pharmaceutical companies at a low cost, while the Simplify Healthcare ETF (PINK) adopts an active management strategy, covering a broader range of healthcare subsectors with a philanthropic component.
In terms of expense ratios, the iShares U.S. Pharmaceutical ETF holds an advantage with a fee of 0.38%, lower than the Simplify Healthcare ETF’s 0.51%. For income-seeking investors, the iShares fund currently offers a higher dividend yield of 1.62%, compared to Simplify’s 0.66%. Regarding fund size, iShares manages $921 million in assets, while Simplify manages $270.7 million. In terms of volatility, IHE has a beta of 0.50, while PINK has a beta of 0.74, indicating that the latter’s price fluctuations are more sensitive to the S&P 500.
As of June 8, 2026, IHE’s total return over the past year was 42.40%, compared to PINK’s 29.30%. Over the past four years, IHE’s maximum drawdown was 15.90%, better than PINK’s 18.80%. Based on an initial investment of $1,000, under the total return over the past four years, IHE would have grown to $1,560, while PINK would have grown to $1,545.
The Simplify Healthcare ETF, launched in 2021, focuses on long-term capital appreciation by investing in 58 innovative healthcare companies across various market capitalizations. Its portfolio consists of approximately 90% healthcare stocks and 10% industrial stocks. Its top three holdings include Purecycle Technologies (10.26%), United Therapeutics Corp (7.32%), and Novo Nordisk (6.67%). The fund has paid $0.16 per share in dividends over the past 12 months and employs a currency hedging strategy. Its unique feature is a philanthropic mission called “Shares for the Cure,” which pledges to donate all net profits to the Susan G. Komen Foundation to fight breast cancer.
In contrast, the iShares U.S. Pharmaceutical ETF, launched in 2006, allocates 100% of its assets to the healthcare sector, focusing on U.S.-based pharmaceutical companies. This fund also holds 58 stocks and has paid $1.49 per share in dividends over the past 12 months. Its top three holdings include Eli Lilly (24.17%), Johnson & Johnson (20.28%), and Royalty Pharma (5.22%). Unlike PINK, which leans toward active management and diversified innovation across biotech and medtech, IHE is highly concentrated in established pharmaceutical giants and has no special arrangements such as charitable donations or currency hedging.
The philanthropic nature of the PINK fund is commendable; the fund manager directs profits toward cancer research, providing investors with a legitimate reason to choose this fund. IHE has significantly outperformed over the past year, delivering a return of approximately 11% year-to-date in 2026, while PINK has fallen nearly 8% over the same period.
